India to China Pharmaceutical Export

The pharmaceutical trade between India and China has experienced significant growth over the past decade. In 2024, India's pharmaceutical exports to China reached approximately $83.99 million, marking a substantial increase from previous years. This upward trajectory reflects the strengthening of bilateral trade relations and India's growing presence in the Chinese pharmaceutical market.

Key milestones include the establishment of the Production Linked Incentive (PLI) scheme by the Indian government, aimed at boosting domestic production and reducing import dependence. This initiative has led to a significant increase in India's exports of active pharmaceutical ingredients (APIs), surpassing imports in the fiscal year 2024-25. Such developments underscore the evolving dynamics of the India-China pharmaceutical trade corridor.

India holds a significant position in China's pharmaceutical import landscape. In 2024, China's pharmaceutical imports from India were valued at $135.68 million, indicating a robust demand for Indian pharmaceutical products. This demand is driven by India's competitive pricing, diverse product offerings, and adherence to international quality standards. While other countries also supply pharmaceuticals to China, India's strategic importance is highlighted by its substantial market share and the growing preference for its products.

Between 2024 and 2026, several developments have influenced the India-China pharmaceutical trade. The Indian government's PLI scheme, launched in 2021, has been instrumental in enhancing domestic manufacturing capabilities and reducing reliance on imports. This initiative has led to a surge in API exports, with exports reaching ₹41,500 crore in the fiscal year 2024-25, surpassing imports of ₹39,215 crore. Additionally, China's rapid ascent in pharmaceutical innovation, with its share of global drug development increasing from 8% in 2015 to 32.3% in 2024, has introduced new dynamics to the market.

Indian pharmaceutical companies seeking to market their products in China must navigate the National Medical Products Administration (NMPA) registration process. This involves appointing a registration legal agent in China to submit the application, as foreign companies cannot apply directly. (gacc.agency) The application dossier must adhere to the Common Technical Document (CTD) format, ensuring comprehensive and standardized documentation. For generic products, clinical trials may not be required, but bioequivalence studies are often necessary. The entire process typically spans 18 to 24 months, depending on the product type and regulatory requirements.

China mandates that foreign manufacturing sites comply with Good Manufacturing Practice (GMP) standards as per NMPA regulations. The inspection process involves a thorough evaluation of manufacturing facilities to ensure adherence to these standards. While China has been working towards mutual recognition agreements with other countries, the extent of such recognition can vary, and companies should stay updated on the latest developments to facilitate smoother market entry.

To import pharmaceutical products into China, Indian exporters must provide several key documents:

• Import License: Authorization from Chinese authorities permitting the importation of specific pharmaceutical products.

• Certificate of Pharmaceutical Product (CPP): Issued by the exporting country's regulatory authority, confirming the product's compliance with national standards.

• Certificate of Analysis (CoA): Details the product's specifications and quality control measures.

• GMP Certificate: Verifies that the manufacturing facility adheres to GMP standards.

Additionally, customs procedures require detailed product information, including labeling and packaging compliance with Chinese regulations.

India's pharmaceutical exports to China are predominantly finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products align with China's healthcare needs, particularly in the treatment of infectious diseases and chronic conditions. For instance, the top export product, Sildenafil Citrate 100 mg tablets, addresses prevalent health issues in China. The demand for such products is driven by China's aging population and the increasing prevalence of lifestyle-related diseases.

The global pharmaceutical landscape is witnessing patent expirations, leading to increased opportunities for generic drugs. India, with its robust generic drug manufacturing capabilities, is well-positioned to capitalize on this trend in China. Additionally, the rising demand for biosimilars presents a significant opportunity for Indian exporters to introduce cost-effective alternatives to expensive biologics in the Chinese market.

China's aging population, coupled with a high disease burden, drives the demand for pharmaceutical imports. The government's increased healthcare spending and initiatives to improve access to medicines further contribute to this demand. These factors create a favorable environment for Indian pharmaceutical exports, as China seeks reliable and cost-effective sources for its growing healthcare needs.

China's Most Favored Nation (MFN) tariff rates for pharmaceutical formulations are generally low, facilitating smoother trade. While preferential rates and duty exemptions may apply under specific trade agreements, Indian exporters should stay informed about the latest tariff structures to optimize their trade strategies.

As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and China concerning pharmaceuticals. However, both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations. Ongoing bilateral discussions may lead to future agreements that could impact pharmaceutical trade.

China's patent laws and data exclusivity provisions can affect the entry of Indian generics into the market. While compulsory licensing exists, it is rarely invoked. Indian exporters must navigate these intellectual property landscapes carefully to ensure compliance and protect their products in the Chinese market.

Major sea routes from Indian ports to China include the routes to Shanghai and Dalian, with transit times typically ranging from 10 to 15 days, depending on the specific ports and shipping conditions. Air freight options are also available, offering faster delivery times but at higher costs. Exporters should consider factors such as shipping costs, transit times, and potential disruptions when planning logistics.

In India, key export ports include Hyderabad ICD (4.5%), Sahar Air Cargo Acc (INBOM4) (7.4%), and J Mata Dee - Chennai FTZ (0.4%). In China, major import ports are Shanghai - Pu Dong (8.5%), Dalian (22.2%), and Shanghai (6.1%). These ports are equipped to handle pharmaceutical shipments, ensuring efficient processing and distribution.

Temperature-controlled logistics are essential for maintaining the efficacy of pharmaceutical products. Good Distribution Practice (GDP) compliance ensures that products are stored and transported under appropriate conditions. Adhering to packaging standards that protect products from environmental factors is crucial for maintaining product quality upon arrival in China.

China's pharmaceutical market is one of the largest globally, with a value exceeding $100 billion. The market is experiencing steady growth, driven by an aging population, increasing healthcare needs, and government initiatives to improve healthcare infrastructure. The share of generics in China's pharmaceutical market is substantial, presenting significant opportunities for Indian exporters.

China's government has implemented various healthcare programs aimed at expanding insurance coverage and improving access to medicines. The drug procurement system, including the National Reimbursement Drug List (NRDL), influences the types of pharmaceuticals in demand. Understanding these systems is vital for Indian exporters to align their products with China's healthcare priorities.

Specific opportunities for Indian exporters include supplying generic versions of high-demand drugs, biosimilars, and products that address prevalent health issues in China. The growth outlook for Indian pharmaceutical exports to China remains positive, supported by competitive pricing, quality standards, and the ability to meet China's evolving healthcare needs.

China imports pharmaceuticals from various countries, including domestic producers, the European Union, and other Asian nations. While domestic production is substantial, the EU and other countries also hold significant market shares. India's market share in China's pharmaceutical imports is notable, reflecting its competitive position.

India's advantages include cost-effective manufacturing, adherence to WHO-GMP compliance, and a broad portfolio of pharmaceutical products. These factors enable Indian exporters to offer high-quality products at competitive prices, appealing